Maxim Group Begins Coverage on Kairos Pharma (NYSEAMERICAN:KAPA)

Maxim Group initiated coverage on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a report released on Thursday morning,Benzinga reports. The brokerage issued a buy rating and a $4.00 price objective on the stock.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price target on shares of Kairos Pharma in a report on Thursday, March 20th.

Kairos Pharma Stock Performance

NYSEAMERICAN KAPA opened at $0.97 on Thursday. The company has a 50 day simple moving average of $1.29. Kairos Pharma has a 12-month low of $0.85 and a 12-month high of $4.00.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.